Anabela Cardoso, MD, is the senior vice president of immunology medical affairs at Eli Lilly and Company.
Reviewing 3 Key Lebrikizumab Abstracts From AAD 2025
Anabela Cardoso, MD, discussed lebrikizumab’s efficacy in improving itch, skin pain, sleep disturbance, and long-term management in atopic dermatitis.
Late-Breaking Data: Baricitinib Shows Rapid Hair Regrowth in Adolescents With Severe Alopecia Areata
Anabela Cardoso, MD, provides data on the phase 3 BRAVE-AA-PEDS trial, the largest JAK inhibitor study dedicated to adolescents with severe alopecia areata, at AAD.
New Survey Confirms Acne Patients Have More Trust in Clinicians than Social Media Influencers
New Meta-Analysis Supports Targeted Vitiligo Therapies
What to Know When Targeting IL-13 vs IL-31 in Atopic Dermatitis
Experts Look Ahead to the Advancements in AD Research